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Abstract
Background: Administration of fluids to restore normovolaemia is one of the most common therapeutic interventions
performed peri-operatively and in the critically ill, but no study has evaluated the importance of infusion rate for the
plasma volume-expanding effect of a resuscitation fluid. The present study is designed to test the hypothesis that a
slow infusion of resuscitation fluid results in better plasma volume expansion than a rapid infusion.
Methods/design: The study is a single-centre, assessor-blinded, parallel-group, randomised prospective study. Patients
over 40 years of age admitted to the post-operative care unit after a Whipple procedure or major gynaecological
surgery and presenting with signs of hypovolaemia are eligible for inclusion. Patients are randomised in a 1:1 fashion
with no stratification to either rapid (30 minutes) or slow (180 minutes) infusion of 5% albumin at a dose of 10 ml/kg
ideal body weight. Plasma volume is measured using 125I human serum albumin at baseline (prior to albumin infusion)
as well as at 30 minutes and 180 minutes after infusion start. The primary endpoint is change in plasma volume from
baseline to 180 minutes after the start of 5% albumin infusion. Secondary endpoints include the integral of plasma
volume over time from baseline to 180 minutes after the start of the infusion and transcapillary escape rate of albumin
(%/h) from 180 minutes to 240 minutes after the start of albumin infusion. In addition, diuresis, change in central
venous oxygen saturation, lactate and blood pressure will be evaluated. A total of 70 patients will be included in the
study, and the study has 80% power to detect a difference of 4 ml/kg in plasma volume expansion between the two
groups.
Discussion: The present study is the first clinical investigation of the importance of infusion rate for the plasma
volume-expanding effect of a resuscitation fluid.
Trial registration: EudraCT identifier: 2013-004446-42. Registration date: 20 December 2013.
ClinicalTrials.gov identifier: NCT02728921. Registration date: 31 March 2016.
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Background
Major surgery initiates a systemic inflammatory response
syndrome (SIRS), which disrupts the normal regulation
of transcapillary fluid exchange with tissue oedema and
hypovolaemia as a consequence. Hypovolaemia will
amplify the inflammatory reaction by reducing cardiac
output and oxygen delivery, which creates a vicious
circle. Fluid therapy is therefore a cornerstone in the
peri-operative treatment of patients undergoing major
surgery as well as in patients with increased vascular
leakage of other aetiologies. However, even if fluid
therapy is life-saving, it is also associated with side ef-
fects such as further oedema formation, coagulopathy
and further endothelial dysfunction. Several studies
indicate that these side effects may adversely affect
outcome following surgery [1, 2]. Also, in other pa-
tient groups with SIRS in the intensive care unit
(ICU), it has been shown that fluid overload is associ-
ated with increased incidence of respiratory failure
and worse outcome [3–6].
From a clinical perspective, it is therefore important
that the fluid administered to antagonize hypovolaemia
remains intravascular as far as possible. Colloids are
macromolecules for which the vessel wall has a low
permeability, and proponents of colloids argue that less
volume is required for equal plasma volume com-
pared with crystalloids. However, extravasation of col-
loids not only is a function of the vessel wall
permeability but also is dependent on the volume of
fluid that is filtered across the capillary wall, which
in turn depends on the transcapillary hydrostatic
pressure [7]. In addition, transient hypervolaemia in-
duced by rapid administration of colloids may induce
increased release of the permeability-increasing diur-
etic agent atrial natriuretic peptide and components
of the endothelial glycocalyx [8, 9].
Taken together, these data indicate that slow adminis-
tration may reduce extravasation of colloids by minimiz-
ing transient hypervolaemia and transient increases in
hydrostatic pressure. This hypothesis is supported by
results derived from two animal model studies of
sepsis-induced systemic inflammatory response show-
ing that the plasma volume expansion was greater in
animals randomised to receive a slow infusion than in
those randomised to receive a rapid infusion of the
same volume of colloid [10, 11].
Fluid administration is one of the most common
therapeutic interventions in ICUs and in post-operative
units around the world [12], and a fluid bolus is a
recommended method to assess fluid responsiveness.
However, to date, no study has addressed the import-
ance of infusion rates in a clinical setting. Although
rapid correction of hypovolaemia makes intuitive sense,
the need for further knowledge in this aspect of fluid
resuscitation was highlighted by the recent Fluid
Expansion as Supportive Therapy trial, which showed
a surprising increase in mortality following a rapid
administration of resuscitation fluids compared with
less aggressive fluid resuscitation [13]. Based on these
considerations, the primary objective of the present
study is to test the hypothesis that plasma volume ex-
pansion of a given volume of colloid is greater if fluid
is administered slowly rather than rapidly.
Methods/design
We are conducting a single-centre, investigator-initiated,
prospective, parallel-group, randomised study of two
different albumin infusion rates in patients following
major abdominal surgery. The study is approved by
the regional ethical vetting board in Lund, Sweden
(Dnr 2014/15), and will be conducted at Skåne University
Hospital in Lund. Overviews of the trial design according
to the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) statement and an overview
of patient flow through the study are presented in Table 1
and Fig. 1, respectively. A SPIRIT checklist is provided in
Additional file 1. Informed consent will be obtained non-
consecutively from eligible participants when a member of
the research team is available. The length of the study will
be from signing of informed consent until 36 ± 7 days
after the start of infusion of the test substance. All patients
will be followed by a study investigator in a visit at the trial
centre. All patients will be evaluated with regard to poten-
tial adverse effects by one of the investigators. The first
patient was included on 18 June 2014. The protocol has
been amended two times. The first amendment ex-
tended inclusion criteria to also include post-operative
patients after major gynaecological surgery to pro-
mote recruitment. The second amendment changed
the interim analysis plan by adding the Haybittle-Peto
approach for the testing of efficacy. In addition, ongoing
vasopressor and inotropic therapy was omitted as an
exclusion criterion. The first amendment was made after
1 patient had been included, and the second was made
after 24 patients had been included. The amendments
were approved by both the regional ethical vetting board
and the Swedish Medical Products Agency (MPA), and
the current protocol version 1.3 2015-04-03 was approved
by MPA 2015-05-27.
Inclusion criteria
Post-operative patients following non-emergent oper-
ation ad modum Whipple procedure or major gynae-
cological cancer surgery at the age of 40 years or
older will be included if fulfilling the following
criteria:
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1. Indication for fluid therapy as judged by the
physician caring for the patient and at least one
of the following criteria is fulfilled within 5 h
after admission to the post-anaesthesia care
unit (PACU):
a. Positive ‘leg-raising test’ (pulse pressure increase
>9% or stroke volume increase by >10% as
measured with cardiac ultrasound [14]
b. Central venous oxygen saturation (ScvO2) <70%
c. Plasma lactate >2.0 mmol/L
d. Urine output <0.5 ml/kg in the hour prior to
inclusion
e. Respiratory variation of the inferior vena cava
>15% as measured by ultrasound [15, 16]
f. Systolic blood pressure <100 mmHg or mean
arterial blood pressure <55 mmHg
2. Written consent by the patient to participate in the
study obtained prior to operation
Exclusion criteria
Patients fulfilling any of the following criteria will be
excluded from the study:
1. Hypersensitivity to the active drug or the tracer
2. Signs of post-operative bleeding
3. History of heart failure
4. The physician caring for the patient considers
that there are strong reasons to administer
another fluid, or the same fluid but in another
way or in a different volume than stated in the
protocol
5. Pregnancy
6. Clinical judgement by the investigator or the treating
physician that the patient should not participate in the
study for reasons other than described above
Informed consent and withdrawal
Patients scheduled for the operative procedures de-
scribed above will be assessed for inclusion. If none of
the pre-operative exclusion criteria are met, a member
of the research team will provide both oral and written
information before surgery (Additional file 2). All
patients will be given the opportunity to ask questions
about the study and will also be given sufficient time to
decide whether to participate. Patients are informed of
their right to withdraw from the study at any time. A
patient who withdraws consent receives standard care.
In addition, the patient/participant may be perman-
ently withdrawn at the investigator’s or the treating
physician’s discretion at any time if this is considered
to be in the patient’s best interest. Predefined per-
manent withdrawal criteria are as follows:
1. Change of surgery procedure to other than
operation ad modumWhipple or major
gynaecological cancer surgery
2. Serious violation of the study protocol, such as
administration of other resuscitation fluid in a
Table 1 Overview of enrolment, interventions and assessments according to the SPIRIT (Standard Protocol Items: Recommendations
for Interventional Trials) statement
Study period
Enrolment Allocation Post-allocation Close-out






Infusion of 5% albumin (10 ml/kg) over 30 minutes X
Infusion of 5% albumin (10 ml/kg) over 180 minutes X
Assessments
Plasma volume X X X
Transcapillary escape rate of albumin X
Haemodynamic data, haematocrit, lactate, ScvO2 X X X X
Post-operative complications X X X X X
Adverse events, serious adverse events X X X X X X
Abbreviations: ScvO2 Central venous oxygen saturation, t1 Baseline, t2 Start of albumin infusion, t3 180 minutes after start of albumin infusion, t4 180–240 minutes
after start of albumin infusion, t5 30 days after operation, t6 36 ± 7 days after inclusion or until resolution of any adverse event, serious adverse event or suspected
unexpected serious adverse reaction
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volume >200 ml within 3 h after start of albumin
infusion
3. Occurrence of known side effects, defined as
serious adverse events (SAEs) listed in the
summary of product characteristics of 5% albumin
or SERALB-125® (IBA-CIS Bio International,
Gif-Sur-Yvette, France) (Side effects that warrant
permanent withdrawal
include anaphylactic shock or pulmonary oedema.)
A record is kept of patients who consented in the pre-
operative screening but were never enrolled (patient
screening log).
Intra- and post-operative care of the patients
Eligible patients who have given consent to participate
in the study will receive routine pre- and intra-operative
care. Anaesthesia will be induced intravenously using
propofol and maintained using either sevoflurane or
desflurane. Patients will receive an epidural catheter for
intra- and post-operative analgesia unless contraindi-
cated. Fentanyl will be used as an analgesic during
induction, and rocuronium will be used as a muscle
relaxant. Crystalloids and colloids will be used as
resuscitation fluids intra-operatively at the discretion
of the attending anaesthetist. A haemoglobin level of
80–90 g/L will be the transfusion trigger. Post-
Fig. 1 Detailed enrolment and randomisation flowchart for Albumin Infusion Rate (AIR) study. PACU Post-anaesthesia care unit, ScvO2 Central venous
oxygen saturation, MAP Mean arterial pressure
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operative maintenance fluids will be a 2.5% or 5%
glucose solution at a rate of 1 ml/kg/h. Analgesics may be
given during the intervention phase of the study, and the
rate of vasoactive agents may be adjusted to maintain
mean arterial pressure >65 mmHg. No fluid other than
maintenance and study fluids may be given during the
intervention period.
Randomisation and blinding
Patients are screened for indications for fluid adminis-
tration during the first 5 h after admission to the PACU
as described above. Patients who fulfil inclusion criteria
and meet no exclusion criteria will be randomised using
a sealed envelope to either rapid or slow infusion of
study drug. The randomisation and preparation of sealed
envelopes are performed by an independent party
(Clinical Research Unit, Skåne University Hospital,
Lund). Randomisation was performed using a compu-
terised random number generator. The research team
is blinded to block size. Measurements of plasma
volumes, transcapillary escape rate (TER) for albumin
and post-operative follow-up will be performed by
members of the research team who are blinded to the
treatment allocation.
Study interventions
Patients randomised to a fast or slow infusion will receive
5% albumin at a dose of 10 ml/kg in 30 minutes or
180 minutes, respectively. Dose is based on ideal body
weight [17]. At 240 minutes after the start of albumin
infusion, the study protocol is completed, and the patient
thereafter receives post-operative care according to local
routine. Figure 2 shows a brief overview of the experimen-
tal protocol. Patients will be in lying position throughout
study protocol time (240 minutes).
Primary outcome
The primary outcome in the study is change in plasma
volume 180 minutes after the start of the albumin
infusion.
Secondary outcomes
Secondary outcomes are differences in plasma volume
over time (integral of plasma volume over time from the
start of albumin infusion from plasma volume PV1 to
PV3) and incidence of post-operative complications up
to 30 days post-operatively (see Additional file 3 for defi-
nitions of complications). Other outcomes of interest are
TER for albumin from 180–240 minutes after the start
of albumin infusion, change in heart rate, change in
central venous oxygen saturation, change in haemoglo-
bin concentration in blood, change in blood pressure,
change in central venous pressure, change in plasma
lactate from the start of albumin infusion to 3 h after
start of infusion, and diuresis from the start of albumin
infusion to 3 h after the start of infusion.
Fig. 2 Detailed experimental protocol. PV1 Baseline plasma volume, PV2 Plasma volume after 30 minutes, PV3 Plasma volume after 180 minutes,
Hct Haematocrit, ScvO2 Central venous oxygen saturation, BP Blood pressure, CVP Central venous pressure, HD Hourly diuresis, TER Transcapillary
escape rate
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In addition, exploratory analyses are planned. These
analyses include measurement of effects of the different
infusion rates on plasma concentration of markers of
endothelial damage and on hormones involved in fluid
homeostasis. For this purpose, blood samples are collected
5 minutes before centrifugation, and plasma samples will
be stored following centrifugation at −80 °C until analysis.
We also intend to analyse to what extent included patients
are hypovolaemic at inclusion (>10% lower than calculated
normal blood volume [18]).
Measurements
Plasma volume is measured using 125I human serum
albumin (HSA) (SERALB-125®) in a total dose of at
most 0.4 MBq. The dose administered to each patient is
recorded in the case report form (CRF, Additional file 4).
The dose in the syringes is determined from their
increased weight multiplied by an activity concentration
from a standard. This standard was prepared from a small
sample from the 125I-HSA vial added to a test tube and
measured for both activity and weight. Blood samples are
collected 5 minutes prior to injection of 125I-HSA
and 10 minutes after injection of 125I-HSA for the
plasma volume calculations. Plasma concentration is
determined in a gamma counter (PerkinElmer 1480
Wizard; PerkinElmer, Waltham, MA, USA), and
plasma volume is calculated by dividing the injected dose
of 125I-HSA by the change in concentration of 125I-HSA
in plasma at 10 minutes post-injection. Injected doses are
corrected for remaining activity in the syringes.
Haematocrit is measured by colorimetric analysis
using a blood gas analyser (Radiometer 850; Radiometer,
Copenhagen, Denmark). Assuming that no blood loss
occurs during the study period, changes in haematocrit
will reflect changes in plasma volume. By this method-
ology, plasma volumes can be estimated every half-hour
during the infusion of albumin. By measuring plasma
volume with 125I-HSA at three different points in time,
the potential effect of alterations in small- to large-vessel
haematocrit can be corrected [19]. The area under the
plasma volume curve will then be calculated for each
patient (plasma volume over time).
The TER for albumin is a measure of leakage of
albumin from microvessels into the microvasculature.
Changes in TER reflect changes in microvascular perme-
ability and changes in parameters influencing convective
transport of albumin such as transvascular hydrostatic
pressure. Plasma concentration of 125I-HSA is measured
at 10 minutes, 30 minutes, 45 minutes and 60 minutes
after the last injection of the tracer. Plasma concentra-
tion of 125I-HSA as a function of time will be plotted in
a log-linear plot. The slope of the line represents TER
and will be expressed as the percentage decrease in
plasma concentration of 125I-HSA per hour [20–22]. For
a summary of measurements, please see Fig. 2.
Data collection and management
All study data will be recorded in CRFs for each patient,
which are kept at the study site. Information on co-
morbidities, medications, results of pre-operative phys-
ical examinations, routine laboratory analysis results,
American Society of Anesthesiologists physical status
classifications, Physiological and Operative Severity Score
for the enUmeration of Mortality and morbidity and Re-
vised Cardiac Risk Index will be collected from the hos-
pital electronic chart system. Peri-operative data will be
collected from the anaesthesia chart, and data that will be
registered include anaesthesia methods and drugs, type
and volume of fluids, peri-operative bleeding, and diur-
esis. Inclusion criteria will be registered in CRFs be-
fore randomisation. Clinical haemodynamic evaluation
will be performed and recorded at inclusion and at 180 mi-
nutes after the start of albumin infusion. Members of the
research team have unlimited access to study data. The
data collected in the present study will be available from
the corresponding author on reasonable request. The
auditing (see below) will include source data verification.
Sample size
Published SD values for plasma volume measured with
the 125I-HSA method are in the range of 4–7 ml/kg [22].
In the present study, we wish to compare differences
in changes in plasma volume, and it is reasonable to
assume that the SD is in the lower part of this range.
In an experimental study, a 50% greater plasma vol-
ume expansion was found after slow administration
of 5% albumin compared with a bolus dose of the
same volume [10]. If we wish to detect a 40% differ-
ence in volume-expanding effect following administra-
tion of 10 ml/kg of 5% albumin, assuming that the
SD of the plasma volume is 5, then about 30 patients
in each group are required to obtain a power of 80%.
To adjust for a slightly lower than expected treatment
effect and for the possibility that patients may not
complete the protocol, we intend to include a total of
70 patients: 35 patients in each arm. Should the number
of patients who complete the protocol be <30 in any of
the treatment groups, we plan to increase the sample size
to maintain power.
Statistical analysis plan
The study will continue until the planned number of
patients has been included, unless the interim analysis
indicates that the study should be stopped. Results will
be unblinded when all data have been collected. Only
patients who received 90% or more of the intended dose
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will be included in the analysis. The investigating team
will perform the statistical analyses.
General analytical principles
1. Analysis will be performed on a per-protocol basis.
2. All hypothesis tests will be two-sided, with a maximal
type I error risk of 0.05.
3. Subgroup analysis will be performed regardless of
overall treatment efficacy.
4. Imputation will not be used to correct for missing
data in the analysis.
Assessment of baseline variables
Baseline variables of patients fulfilling study protocol in
the two study arms will be tabulated. Discrete variables
will be reported as frequencies and percentages, and
continuous variables will be reported as either means
with SDs or medians with interquartile ranges.
Analysis of outcomes
The primary outcome will be analysed using Student’s
t test. Secondary outcomes will be analysed using
Student’s t test or the Mann-Whitney U test as appropri-
ate. Differences between the groups will be reported as
means with 95% confidence intervals. In the event of no
difference between the groups with regard to primary
outcome and a difference in the secondary outcome of
plasma volume over time, we will interpret these results as
supporting our hypothesis but that confirmatory studies
are needed. With the exception of number of complica-
tions, all other outcomes are regarded as exploratory, and
no emphasis will be placed on differences between the
treatment groups, should the primary outcome and
plasma volume over time outcome be negative.
Subgroup analysis
A sensitivity analysis using multivariate regression will
be performed to assess if treatment effect is dependent
on type of surgery and baseline plasma volume.
Auditing
The purpose of auditing and quality control is to ensure
scientific integrity, data quality, the safety and integrity
of the participating subjects, and that the study is com-
pliant with the current versions of the Declaration of
Helsinki, the International Council for Harmonisation
of Technical Requirements for Pharmaceuticals for
Human Use, good clinical practice and national regula-
tions. The sponsor will delegate auditing to the Clinical
Research Unit, Skåne University Hospital in Lund, an
independent party that will perform on-site monitoring
before, during and after the study. Considering that the
patients will be treated according to normal routine
during major abdominal surgery, that the infusion rates
and volumes are within the normal range, and the low
frequency of adverse events (AEs) in an earlier large pro-
spective randomised clinical trial comparing albumin with
normal saline in an ICU setting, the study will be per-
formed without the use of a data monitoring board [23].
Interim analysis
An independent statistician will perform an interim
analysis for assessment of efficacy and futility after 36
patients have completed the protocol. The Haybittle-
Peto approach will be used when testing for efficacy. If a
difference with regard to the primary endpoint with
p ≤ 0.001 is detected, the study may be stopped. Futility
will be assessed by simulating the remainder of the study
multiple times using an SD of 5 and a difference in means
of 4 ml/kg between the two groups. The results of each
simulation will be combined with the obtained data. If the
simulated data in combination with the observed data
show a significant effect (two-sided Student’s t test with
an α <0.05) in less than 10% of the cases, the study will be
stopped. Should the observed SD in interim analysis be
higher than that used in the power calculation, the higher
number will be used for the simulation. The principal
investigator has the authority to stop the trial.
Harms
All patients are evaluated with regard to potential AEs
or SAEs by one of the investigators, and potential AEs
and SAEs are recorded in the CRF. A SAE is defined as
an event that fulfils one or more of the following criteria:
results in death, is life-threatening, requires prolongation
of hospitalisation, results in persistent or significant
disability or incapacity or any other important medical
event. The investigator evaluating the patient at the end
of the study is responsible for the treatment of any AE
or SAE until resolution of the AE or SAE. Depending on
the nature of the AE or SAE, the treatment will take
place at either the trial centre, the local hospital or as an
outpatient. If the responsible investigator/sponsor judges
the SAE as being drug-related and unexpected, this must
be promptly reported to the sponsor, which is respon-
sible for reporting suspected unexpected serious adverse
reactions to the Swedish MPA and the regional ethical
vetting board.
Publication plan
The study is registered in the European Clinical
Trials Database (EudraCT 2013-004446-42) and the
ClinicalTrials.gov database (NCT02728921). Following
completion of the trial, the main manuscript will be
submitted to a peer-reviewed journal, regardless of the
trial outcome. For publication of the main outcomes, the
first figure presented will be a Consolidated Standards
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of Reporting Trials (CONSORT) flowchart. The diagram
will include the number of screened patients, the number
of patients giving consent, the number of patients
meeting all inclusion criteria, the number of patients
randomised to each of the two treatment arms, and
the number of patients completing the protocol in
each of the treatment groups. The second figure will
depict plasma volumes in the respective groups at
baseline and at 30 minutes and 180 minutes after the
start of albumin infusion. The first table will describe
baseline demographics as detailed above. The second
table will describe secondary outcomes. Authorship will
be granted according to the criteria described by the
International Committee of Medical Journal Editors [24].
Funding and sponsor
The AIR trial is funded by Region Skåne (Medical
Training and Research Agreement [Avtal om Läkarut-
bildning och Forskning]), the Gyllenstiernska Krapperup
Foundation and the Anna and Edwin Berger Foundation.
Other than funding, the funders have no role in any aspect
of the trial. The study principal investigator (PB) is also
sponsor as delegated by Skåne University Hospital.
Discussion
The AIR study will provide clinical data on the im-
portance of infusion rate for the plasma volume-
expanding effect of colloids in patients with suspected
hypovolaemia after major abdominal surgery. The
decision to include patients subjected to a Whipple
procedure or major gynaecological surgery is based
on the clinical experience that these patients often
appear hypovolaemic in the immediate post-operative
period and thus are likely to require fluid resuscita-
tion. Post-operative hypovolaemia in these patients is
at least partly due to vascular leak secondary to the
systemic inflammatory response initiated by the oper-
ation, and these patients are therefore likely to share
pathophysiological mechanisms with other critically ill
patients requiring fluid resuscitation [25]. Given the
transient nature of the need for fluid resuscitation in
the majority of these post-operative patients, the immedi-
ate post-operative period was believed to represent the
optimal time point for our purposes.
Albumin is chosen as the study colloid because
albumin is a naturally occurring colloid with very few
contraindications in the current setting and with an
excellent safety record [23]. The rates of infusion are
chosen to differ as much as possible within the range
of clinical practice for this patient category. In routine
clinical practice, the anaesthesiologist caring for the pa-
tient decides how quickly 5% albumin is to be adminis-
tered, and the rates and doses to be tested are within
the limits normally used in our institution as well as
in others, and they do not differ from our clinical
routine [26, 27].
Plasma volume measurement using 125I-HSA is
considered to be the gold standard for measurement of
plasma volume and is used clinically in many hospitals
worldwide. The radiation dose received by the pa-
tients due to participation in the study is approxi-
mately 0.12 mSv and is less than the background
radiation that patients are naturally exposed to during
a 6-month period, and also <0.1% of the dose used
during radioiodine treatment of hyperthyroidism.
Therefore, in accordance with World Health Organ-
isation guidelines, patients will not receive treatment
with potassium iodide to block thyroid uptake of
radiolabelled iodine.
Measurement of TER for albumin is commonly used
to evaluate vascular leak of albumin. After a bolus dose
of 125I-has, there is a steep decline in plasma concentra-
tion during the first 10 minutes, which is thought to
represent mixing and distribution into a rapidly equili-
brating space. After the first 10 minutes, the rate of
decline in plasma concentration of 125I-HSA reflects
extravasation and a gradual increase in lymphatic return
of the tracer. To minimize the influence of lymphatic
return on the decrease in in plasma concentration of
tracer, TER is measured during the first hour after injec-
tion. It could be argued that recirculation of 125I-HSA
from the two preceding plasma volume measurements
(see Fig. 1) could influence the TER measurement.
The magnitude of this influence during the 4-h
experimental period can be modelled by assuming a
TER value of 15%, a ratio of 1:4 between the intravas-
cular and interstitial extracellular compartments. On
the basis of these assumptions, it can be estimated
that recirculation will have a negligible influence on a
difference in TER between the two treatment groups
(Additional file 5). This conclusion aligns with results
from a similar analysis concerning repeated TER mea-
surements in patients with sepsis [28].
Trial status
Recruitment has been completed. The interim analysis
has been performed, and no reason to halt the study has
been found. No SAEs have been registered to date.
Additional files
Additional file 1: SPIRIT Checklist. (DOC 99 kb)
Additional file 2: Consent form (in Swedish). (DOCX 32 kb)
Additional file 3: Definition of postoperative complications. (PDF 108 kb)
Additional file 4: Case report form (in Swedish). (DOCX 258 kb)
Additional file 5: Effect of tracer recirculation on measuremnet of
transcapillary escape rate for albumin. (DOCX 158 kb)
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